+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neuropathy Pain Treatment Market Research Report by Pain Type, Indication, Treatment, Distribution Channel, End-User, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 140 Pages
  • January 2023
  • Region: United States
  • 360iResearch™
  • ID: 5667622
UP TO OFF until Mar 31st 2023
The United States Neuropathy Pain Treatment Market size was estimated at USD 1,455.44 million in 2022, USD 1,595.75 million in 2023 and is projected to grow at a CAGR of 11.12% to reach USD 3,384.27 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Neuropathy Pain Treatment Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Neuropathy Pain Treatment Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Neuropathy Pain Treatment Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Neuropathy Pain Treatment Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Neuropathy Pain Treatment Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Pain Type, the market is studied across Coccydynia, Entrapment Neuropathy, Foot Pain, Peripheral Neuropathy, Phantom Limb Neuropathy, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, and Trigeminal Neuralgia.
  • Based on Indication, the market is studied across Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Spinal Stenosis.
  • Based on Treatment, the market is studied across Drugs and Therapy. The Drugs is is further studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is is further studied across Ibuprofen and Naproxen.
  • Based on Distribution Channel, the market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
  • Based on End-User, the market is studied across Clinics and Hospitals.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Neuropathy Pain Treatment Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Neuropathy Pain Treatment Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Neuropathy Pain Treatment Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Neuropathy Pain Treatment Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Neuropathy Pain Treatment Market, including Abbott Laboratories, Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson Services, Inc., Novartis AG, Pfizer Inc., and Sun Pharmaceutical Industries Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Neuropathy Pain Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Neuropathy Pain Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Neuropathy Pain Treatment Market?
4. What is the competitive strategic window for opportunities in the United States Neuropathy Pain Treatment Market?
5. What are the technology trends and regulatory frameworks in the United States Neuropathy Pain Treatment Market?
6. What is the market share of the leading vendors in the United States Neuropathy Pain Treatment Market?
7. What modes and strategic moves are considered suitable for entering the United States Neuropathy Pain Treatment Market?
Frequently Asked Questions about the U.S. Neuropathy Pain Treatment Market

What is the estimated value of the U.S. Neuropathy Pain Treatment Market?

The U.S. Neuropathy Pain Treatment Market was estimated to be valued at $1455.44 Million in 2022.

What is the growth rate of the U.S. Neuropathy Pain Treatment Market?

The growth rate of the U.S. Neuropathy Pain Treatment Market is 11.1%, with an estimated value of $3384.27 Million by 2030.

What is the forecasted size of the U.S. Neuropathy Pain Treatment Market?

The U.S. Neuropathy Pain Treatment Market is estimated to be worth $3384.27 Million by 2030.

Who are the key companies in the U.S. Neuropathy Pain Treatment Market?

Key companies in the U.S. Neuropathy Pain Treatment Market include Abbott Laboratories, Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company and Eli Lilly and Company.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Neuropathy Pain Treatment Market, by Pain Type
6.1. Introduction
6.2. Coccydynia
6.3. Entrapment Neuropathy
6.4. Foot Pain
6.5. Peripheral Neuropathy
6.6. Phantom Limb Neuropathy
6.7. Post Herpetic Neuralgia (PHN)
6.8. Post Traumatic Neuropathy
6.9. Trigeminal Neuralgia
7. Neuropathy Pain Treatment Market, by Indication
7.1. Introduction
7.2. Chemotherapy-Induced Peripheral Neuropathy
7.3. Diabetic Neuropathy
7.4. Spinal Stenosis
8. Neuropathy Pain Treatment Market, by Treatment
8.1. Introduction
8.2. Drugs
8.3.1. Antidepressant Drugs Type
8.3.2.1. Serotonin Noradrenaline
8.3.2.2. Tricyclic Antidepressants
8.3.2. Medication Type
8.3.3. Multimodal Therapy
8.3.4. NSAIDs Type
8.3.5.1. Ibuprofen
8.3.5.2. Naproxen
8.3. Therapy
9. Neuropathy Pain Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Online Pharmacies
9.3. Retail Pharmacies & Drug Stores
10. Neuropathy Pain Treatment Market, by End-User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
11. California Neuropathy Pain Treatment Market
11.1. Introduction
12. Florida Neuropathy Pain Treatment Market
12.1. Introduction
13. Illinois Neuropathy Pain Treatment Market
13.1. Introduction
14. New York Neuropathy Pain Treatment Market
14.1. Introduction
15. Ohio Neuropathy Pain Treatment Market
15.1. Introduction
16. Pennsylvania Neuropathy Pain Treatment Market
16.1. Introduction
17. Texas Neuropathy Pain Treatment Market
17.1. Introduction
18. Competitive Landscape
18.1. FPNV Positioning Matrix
18.1.1. Quadrants
18.1.2. Business Strategy
18.1.3. Product Satisfaction
18.2. Market Ranking Analysis, By Key Player
18.3. Market Share Analysis, By Key Player
18.4. Competitive Scenario
18.4.1. Merger & Acquisition
18.4.2. Agreement, Collaboration, & Partnership
18.4.3. New Product Launch & Enhancement
18.4.4. Investment & Funding
18.4.5. Award, Recognition, & Expansion
19. Company Usability Profiles
19.1. Abbott Laboratories
19.1.1. Business Overview
19.1.2. Key Executives
19.1.3. Product & Services
19.2. Assertio Therapeutics Inc.
19.2.1. Business Overview
19.2.2. Key Executives
19.2.3. Product & Services
19.3. Astellas Pharma Inc.
19.3.1. Business Overview
19.3.2. Key Executives
19.3.3. Product & Services
19.4. AstraZeneca Plc
19.4.1. Business Overview
19.4.2. Key Executives
19.4.3. Product & Services
19.5. Aurobindo Pharma Ltd.
19.5.1. Business Overview
19.5.2. Key Executives
19.5.3. Product & Services
19.6. Baxter International Inc.
19.6.1. Business Overview
19.6.2. Key Executives
19.6.3. Product & Services
19.7. Biogen Inc.
19.7.1. Business Overview
19.7.2. Key Executives
19.7.3. Product & Services
19.8. Bristol Myers Squibb Company
19.8.1. Business Overview
19.8.2. Key Executives
19.8.3. Product & Services
19.9. Depomed, Inc.
19.9.1. Business Overview
19.9.2. Key Executives
19.9.3. Product & Services
19.10. Dr. Reddy’s Laboratories Ltd.
19.10.1. Business Overview
19.10.2. Key Executives
19.10.3. Product & Services
19.11. Eli Lilly and Company
19.11.1. Business Overview
19.11.2. Key Executives
19.11.3. Product & Services
19.12. Endo International Plc
19.12.1. Business Overview
19.12.2. Key Executives
19.12.3. Product & Services
19.13. GlaxoSmithKline Plc
19.13.1. Business Overview
19.13.2. Key Executives
19.13.3. Product & Services
19.14. Johnson and Johnson Services, Inc.
19.14.1. Business Overview
19.14.2. Key Executives
19.14.3. Product & Services
19.15. Mallinckrodt Pharmaceuticals
19.15.1. Business Overview
19.15.2. Key Executives
19.15.3. Product & Services
19.16. Novartis AG
19.16.1. Business Overview
19.16.2. Key Executives
19.16.3. Product & Services
19.17. Pfizer Inc.
19.17.1. Business Overview
19.17.2. Key Executives
19.17.3. Product & Services
19.18. Sanofi
19.18.1. Business Overview
19.18.2. Key Executives
19.18.3. Product & Services
19.19. Sun Pharmaceutical Industries Ltd
19.19.1. Business Overview
19.19.2. Key Executives
19.19.3. Product & Services
19.20. Teva Pharmaceutical Industries Ltd.
19.20.1. Business Overview
19.20.2. Key Executives
19.20.3. Product & Services
19.21. VistaGen Therapeutics Inc.
19.21.1. Business Overview
19.21.2. Key Executives
19.21.3. Product & Services
20. Appendix
20.1. Discussion Guide
20.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET DYNAMICS
FIGURE 8. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY PAIN TYPE, 2027
FIGURE 11. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COCCYDYNIA, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ENTRAPMENT NEUROPATHY, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY FOOT PAIN, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHANTOM LIMB NEUROPATHY, 2018-2027 (USD MILLION)
FIGURE 16. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST HERPETIC NEURALGIA (PHN), 2018-2027 (USD MILLION)
FIGURE 17. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST TRAUMATIC NEUROPATHY, 2018-2027 (USD MILLION)
FIGURE 18. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2021 VS 2027 (%)
FIGURE 20. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2021 VS 2027 (USD MILLION)
FIGURE 21. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2027
FIGURE 22. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, 2018-2027 (USD MILLION)
FIGURE 23. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, 2018-2027 (USD MILLION)
FIGURE 24. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL STENOSIS, 2018-2027 (USD MILLION)
FIGURE 25. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2021 VS 2027 (%)
FIGURE 26. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2021 VS 2027 (USD MILLION)
FIGURE 27. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT, 2027
FIGURE 28. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2027 (USD MILLION)
FIGURE 30. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SEROTONIN NORADRENALINE, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2027 (USD MILLION)
FIGURE 32. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MEDICATION TYPE, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MULTIMODAL THERAPY, 2018-2027 (USD MILLION)
FIGURE 34. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2027 (USD MILLION)
FIGURE 35. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY IBUPROFEN, 2018-2027 (USD MILLION)
FIGURE 36. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NAPROXEN, 2018-2027 (USD MILLION)
FIGURE 37. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2027 (USD MILLION)
FIGURE 38. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 39. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 40. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2027
FIGURE 41. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
FIGURE 42. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, 2018-2027 (USD MILLION)
FIGURE 43. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2021 VS 2027 (%)
FIGURE 44. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2021 VS 2027 (USD MILLION)
FIGURE 45. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USER, 2027
FIGURE 46. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINICS, 2018-2027 (USD MILLION)
FIGURE 47. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
FIGURE 48. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 55. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 56. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 57. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COCCYDYNIA, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COCCYDYNIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ENTRAPMENT NEUROPATHY, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ENTRAPMENT NEUROPATHY, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY FOOT PAIN, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY FOOT PAIN, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHANTOM LIMB NEUROPATHY, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHANTOM LIMB NEUROPATHY, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST HERPETIC NEURALGIA (PHN), 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST HERPETIC NEURALGIA (PHN), BY STATE, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST TRAUMATIC NEUROPATHY, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST TRAUMATIC NEUROPATHY, BY STATE, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY STATE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY STATE, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY STATE, 2018-2027 (USD MILLION)
TABLE 27. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL STENOSIS, 2018-2027 (USD MILLION)
TABLE 28. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL STENOSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 29. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 30. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2027 (USD MILLION)
TABLE 31. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, BY STATE, 2018-2027 (USD MILLION)
TABLE 32. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2027 (USD MILLION)
TABLE 33. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY STATE, 2018-2027 (USD MILLION)
TABLE 34. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SEROTONIN NORADRENALINE, 2018-2027 (USD MILLION)
TABLE 35. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SEROTONIN NORADRENALINE, BY STATE, 2018-2027 (USD MILLION)
TABLE 36. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2027 (USD MILLION)
TABLE 37. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY STATE, 2018-2027 (USD MILLION)
TABLE 38. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MEDICATION TYPE, 2018-2027 (USD MILLION)
TABLE 39. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MEDICATION TYPE, BY STATE, 2018-2027 (USD MILLION)
TABLE 40. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MULTIMODAL THERAPY, 2018-2027 (USD MILLION)
TABLE 41. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MULTIMODAL THERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 42. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2027 (USD MILLION)
TABLE 43. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, BY STATE, 2018-2027 (USD MILLION)
TABLE 44. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY IBUPROFEN, 2018-2027 (USD MILLION)
TABLE 45. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY IBUPROFEN, BY STATE, 2018-2027 (USD MILLION)
TABLE 46. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NAPROXEN, 2018-2027 (USD MILLION)
TABLE 47. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NAPROXEN, BY STATE, 2018-2027 (USD MILLION)
TABLE 48. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2027 (USD MILLION)
TABLE 49. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 50. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 51. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2027 (USD MILLION)
TABLE 52. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2018-2027 (USD MILLION)
TABLE 53. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, 2018-2027 (USD MILLION)
TABLE 54. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY STATE, 2018-2027 (USD MILLION)
TABLE 55. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 56. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINICS, 2018-2027 (USD MILLION)
TABLE 57. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 58. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
TABLE 59. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2027 (USD MILLION)
TABLE 60. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 61. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 62. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 63. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 64. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 65. CALIFORNIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 66. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 67. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 68. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 69. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 70. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 71. FLORIDA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 72. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 73. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 74. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 75. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 76. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 77. ILLINOIS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 78. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 79. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 80. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 81. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 82. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 83. NEW YORK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 84. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 85. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 86. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 87. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 88. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 89. OHIO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 90. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 91. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 92. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 93. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 94. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 95. PENNSYLVANIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 96. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 97. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2027 (USD MILLION)
TABLE 98. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 99. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2027 (USD MILLION)
TABLE 100. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 101. TEXAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2027 (USD MILLION)
TABLE 102. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 103. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 104. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 105. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET RANKING, BY KEY PLAYER, 2021
TABLE 106. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
TABLE 107. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET MERGER & ACQUISITION
TABLE 108. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 109. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 110. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET INVESTMENT & FUNDING
TABLE 111. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 112. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited

Methodology

Loading
LOADING...